Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vasileios Bekiaris has a total of 214 co-authors. Here are the top co-authors by number of shared publications:

  • Graham Anderson

    Department of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK

    13 shared publications
  • David R. Withers

    Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK

    12 shared publications
  • Fabrina Gaspal

    MRC Centre for Immune Regulation, Institute for Biomedical Research, Birmingham Medical School, Birmingham, UK

    8 shared publications
  • Fiona M. McConnell

    MRC Centre for Immune Regulation, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

    7 shared publications
  • Mi-Yeon Kim

    Department of Bioinformatics and Life Sciences, Soongsil University , Seoul

    7 shared publications
  • John Rizk

    LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

    6 shared publications

Latest Publications

  • A temporal differentiation program after birth delineates γδ T cell immunity

    by Maria V. Baglioni, Marcelo G. F. Fares da Silva, Andrea Sonnenholzner, John Rizk, Alastair Copland, Elisa Catafal-Tardos, Davide Secci, Paula Peñalver-Sebastián, Martin F. Laursen, Susanne S. Kappel, et al.

    Type 1 and type 3 γδ T cells develop in the embryonic thymus, yet it is not known whether they continue to differentiate after birth in tissues. Here, we show that in the first week of life, intestinal γδ T cells up-regulated many T cell activation and type 3 genes, while the postweaning period was dominated by induction of genes related to effector function, type 1 immunity, and cytotoxicity. During this period, γδ T cells protected the gut from fungal infection. In the adult intestine, type 3 interleukin-17–producing γδ T cells (γδT17 cells) had a distinct phenotype, a Tbet-dependent type 1 immune profile and enhanced T cell receptor (TCR) signaling. Last, we found a γδT17 cell–like population in the neonatal human gut. Collectively, our data suggest that γδ T cells continue to mature after they leave the thymus and, upon localization to the gut, a dynamic temporal differentiation program reshapes type 3 cells into Tbet + type 1 effectors with heightened TCR activity.

  • Open Access

    Biomaterials for Improving Skin Penetration in Treatment of Skin Cancer

    by Davide Secci, Andrew Urquhart, Vasileios Bekiaris, Katrine Qvortrup

    Skin cancer is among the most common malignancies worldwide, posing a significant societal burden due to its increasing incidence and its limited responsiveness to conventional topical therapies. Treatment is challenged by the presence of the skin barrier which restricts drug penetration. This review discusses the structural and physiological challenges of topical delivery and summarizes efforts to develop functional biomaterials to enhance skin drug penetration. Important aspects to consider when developing formulation strategies, such as drug properties and release mechanisms, are discussed alongside current limitations and future perspectives.


  • Open Access

    Dynamics of checkpoint receptors in γδ T cell subsets are associated with clinical response during anti-PD-1 immunotherapies

    by Elisa Catafal-Tardos, Lola Dachicourt, Maria Virginia Baglioni, Marcelo Gregorio Filho Fares da Silva, Davide Secci, Marco Donia, Anders Handrup Kverneland, Inge Marie Svane, Vasileios Bekiaris

    Gamma delta (γδ) T cells are innate-like lymphocytes with potent anti-tumor properties. Herein, we show that immune checkpoint receptors (ICRs) display differential expression and regulation by the JAK-STAT pathway in Vδ1 and Vδ2 cells and identify constitutive (e.g. TIGIT, PD-1) and inducible (e.g. TIM-3, LAG-3, CTLA-4) ICRs. In melanoma, all γδ T cell subsets downregulated AP-1 transcription factors, but Vδ1 cells specifically expressed high levels of ICR, TOX and inhibitory killer Ig-like receptor (KIR) transcripts, reminiscent of exhaustion. However, patient-derived cells were functionally competent, although induction of LAG-3 and CTLA-4 was impaired. During anti-PD-1 monotherapy, Vδ1 cells specifically bound high levels of therapeutic antibody but only in patients who responded to treatment, revealing a potential new prognostic marker for evaluating the efficacy of IC blockade (ICB) therapy. Finally, expression of KIR genes in Vδ1 cells was downregulated in response to successful ICB therapy. Collectively, our data indicate an intricate relationship between ICRs and γδ T cells and reveal novel approaches by which these cells can be harnessed in order to discern or improve cancer immunotherapy.


  • Open Access

    Checkpoint receptors in circulating γδ T cells can discern the outcome of cancer immunotherapy

    by Elisa Catafal Tardos, Lola Dachicourt, Maria Virginia Baglioni, Marcelo Gregorio Filho Fares da Silva, Davide Secci, Marco Donia, Anders Kverneland, Inge Marie Svane, Vasileios Bekiaris

    Gamma delta (γδ) T cells are innate-like lymphocytes that in humans can be broadly classified into two main subtypes based on their unique TCRδ chain, Vδ1 and Vδ2. Both subsets have potent anti-tumor properties and the presence of Vδ1 cells in the tumor is often associated with positive prognosis. Herein, we investigated the molecular interplay between immune checkpoint receptors (ICRs), IC blockade (ICB) therapy and γδ T cells. We show that ICRs display differential expression and regulation by the JAK-STAT pathway in circulating Vδ1 and Vδ2 cells and identify constitutive (e.g. TIGIT, PD-1) and inducible (e.g. TIM-3, LAG-3, CTLA-4) ICRs. In melanoma, Vδ1 cells, especially in patients who did not respond to ICB or required combination therapy, expressed high levels of ICR, TOX and inhibitory killer Ig-like receptors (KIR) transcripts, reminiscent of an exhaustion transcriptional signature. At the same time all γδ T cells had a prominent downregulation in AP-1 transcription factors. Patient derived cells were functionally competent, although induction of LAG-3 and CTLA-4 was impaired. In the context of anti-PD-1 monotherapy, Vδ1 cells specifically bound high levels of therapeutic antibody but only in patients who responded to treatment, revealing a potential new prognostic marker for evaluating the efficacy of ICB therapy. Finally, expression of KIR genes in Vδ1 cells was downregulated in response to successful ICB therapy. Collectively, our data indicate an intricate relationship between ICRs, putatively also KIRs, and γδ T cells and reveal novel approaches by which these cells can be harnessed in order to discern or improve cancer immunotherapy.


  • Open Access

    IL-27 maintains cytotoxic Ly6C+ γδ T cells that arise from immature precursors

    by Robert Wiesheu, Sarah C Edwards, Ann Hedley, Holly Hall, Marie Tosolini, Marcelo Gregorio Filho Fares da Silva, Nital Sumaria, Suzanne M Castenmiller, Leyma Wardak, Yasmin Optaczy, et al.

    In mice, γδ-T lymphocytes that express the co-stimulatory molecule, CD27, are committed to the IFNγ-producing lineage during thymic development. In the periphery, these cells play a critical role in host defense and anti-tumor immunity. Unlike αβ-T cells that rely on MHC-presented peptides to drive their terminal differentiation, it is unclear whether MHC-unrestricted γδ-T cells undergo further functional maturation after exiting the thymus. Here, we provide evidence of phenotypic and functional diversity within peripheral IFNγ-producing γδ T cells. We found that CD27 + Ly6C − cells convert into CD27 + Ly6C + cells, and these CD27 + Ly6C + cells control cancer progression in mice, while the CD27 + Ly6C − cells cannot. The gene signatures of these two subsets were highly analogous to human immature and mature γδ-T cells, indicative of conservation across species. We show that IL-27 supports the cytotoxic phenotype and function of mouse CD27 + Ly6C + cells and human Vδ2 + cells, while IL-27 is dispensable for mouse CD27 + Ly6C − cell and human Vδ1 + cell functions. These data reveal increased complexity within IFNγ-producing γδ-T cells, comprising immature and terminally differentiated subsets, that offer new insights into unconventional T-cell biology.


  • Open Access

    IL-27 maintains cytotoxic Ly6C + γδ T cells that arise from immature precursors

    by Robert Wiesheu, Sarah C. Edwards, Ann Hedley, Marie Tosolini, Marcelo Gregorio Filho Fares da Silva, Nital Sumaria, Yasmin Optaczy, David G. Hill, Alan J. Hayes, Jodie Hay, et al.

    In mice, γδ T cells that express the co-stimulatory molecule, CD27, are committed to the IFNγ-producing lineage in the thymus, and in the periphery, these cells play a critical role in host defence and anti-tumor immunity. Unlike αβ T cells that rely on MHC-presented peptides to drive their terminal differentiation, it is unclear whether MHC-unrestricted γδ T cells undergo further functional maturation after exiting the thymus. Here, we provide evidence of phenotypic and functional diversity within peripheral IFNγ-producing γδ T cells. We found that immature CD27 + Ly6C — cells convert into mature CD27 + Ly6C + cells, and these mature cells control cancer progression while the immature cells cannot. The gene signatures of these two subsets were highly analogous to human immature and mature γδ T cells, indicative of conservation across species. We show that IL-27 supports the cytotoxic phenotype and function of mouse CD27 + Ly6C + cells and human Vδ2 + cells, while IL-27 is dispensable for mouse CD27 + Ly6C — cells and human Vδ1 + cells. These data reveal increased complexity within IFNγ-producing γδ T cells, comprising of immature and terminally differentiated subsets, that offer new insights into unconventional T cell biology.


  • Open Access

    The cIAP ubiquitin ligases sustain type 3 γδ T cells and ILC during aging to promote barrier immunity

    by John Rizk, Urs M. Mörbe, Rasmus Agerholm, Maria Virginia Baglioni, Elisa Catafal Tardos, Marcelo Gregorio Filho Fares da Silva, Isabel Ulmert, Darshana Kadekar, Monica Torrellas Viñals, Vasileios Bekiaris

    Early-life cues shape the immune system during adulthood. However, early-life signaling pathways and their temporal functions are not well understood. Herein, we demonstrate that the cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/2), which are E3 ubiquitin ligases, sustain interleukin (IL)-17–producing γ δ T cells (γδT17) and group 3 innate lymphoid cells (ILC3) during late neonatal and prepubescent life. We show that cell-intrinsic deficiency of cIAP1/2 at 3–4 wk of life leads to downregulation of the transcription factors cMAF and RORγt and failure to enter the cell cycle, followed by progressive loss of γδT17 cells and ILC3 during aging. Mice deficient in cIAP1/2 have severely reduced γδT17 cells and ILC3, present with suboptimal γδT17 responses in the skin, lack intestinal isolated lymphoid follicles, and cannot control intestinal bacterial infection. Mechanistically, these effects appear to be dependent on overt activation of the non-canonical NF-κB pathway. Our data identify cIAP1/2 as early-life molecular switches that establish effective type 3 immunity during aging.


  • Open Access

    The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma

    by Susann Schönefeldt, Tamara Wais, Marco Herling, Satu Mustjoki, Vasileios Bekiaris, Richard Moriggl, Heidi A. Neubauer

    γδ T cells are unique players in shaping immune responses, lying at the intersection between innate and adaptive immunity. Unlike conventional αβ T cells, γδ T cells largely populate non-lymphoid peripheral tissues, demonstrating tissue specificity, and they respond to ligands in an MHC-independent manner. γδ T cells display rapid activation and effector functions, with a capacity for cytotoxic anti-tumour responses and production of inflammatory cytokines such as IFN-γ or IL-17. Their rapid cytotoxic nature makes them attractive cells for use in anti-cancer immunotherapies. However, upon transformation, γδ T cells can give rise to highly aggressive lymphomas. These rare malignancies often display poor patient survival, and no curative therapies exist. In this review, we discuss the diverse roles of γδ T cells in immune surveillance and response, with a particular focus on cancer immunity. We summarise the intriguing dichotomy between pro- and anti-tumour functions of γδ T cells in solid and haematological cancers, highlighting the key subsets involved. Finally, we discuss potential drivers of γδ T-cell transformation, summarising the main γδ T-cell lymphoma/leukaemia entities, their clinical features, recent advances in mapping their molecular and genomic landscapes, current treatment strategies and potential future targeting options.


  • Type I interferon supports γδ T‐cell homeostasis and immunity through direct and indirect receptor signaling in mice

    by Rasmus Agerholm, Darshana Kadekar, John Rizk, Vasileios Bekiaris

    Interleukin (IL)‐17‐producing gamma delta (γδ) T (γδT17) cells are an essential part of innate type 3 immunity against numerous pathogens. At the same time, a large body of evidence from mouse models and human clinical studies suggests that γδT17 cells contribute to the pathogenesis of many inflammatory diseases as well as cancer. It is therefore relevant to elucidate their immunobiology in detail and identify molecules and pathways that can regulate their function. Herein, we investigated the importance of the type I interferon (IFN) signaling system in γδT17 homeostasis and activation. We found that the IFN alpha receptor 1 (IFNAR1) was critical to maintain their normal homeostasis and to promote their activation during cutaneous inflammation. However, this did not require γδT17‐intrinsic expression of IFNAR1. In contrast, expression of IFNAR1 by γδT17 cells was required in order to suppress IL‐17 production during viral infection. Our data delineate direct from indirect IFNAR1 signaling and reveal an important immunoregulatory role for both tonic and inducible type I IFN in γδT17 cells.


  • Open Access

    Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells

    by Elisa Catafal-Tardos, Maria Virginia Baglioni, Vasileios Bekiaris

    In recent years, checkpoint inhibitor (CPI) therapy has shown promising clinical responses across a broad range of cancers. However, many patients remain unresponsive and there is need for improvement. CPI therapy relies on antibody-mediated neutralization of immune inhibitory or checkpoint receptors (ICRs) that constitutively suppress leukocytes. In this regard, the clinical outcome of CPI therapy has primarily been attributed to modulating classical MHC-restricted αβ T cell responses, yet, it will inevitably target most lymphoid (and many myeloid) populations. As such, unconventional non-MHC-restricted gamma delta (γδ) T, mucosal associated invariant T (MAIT) and natural killer T (NKT) cells express ICRs at steady-state and after activation and may thus be affected by CPI therapies. To which extent, however, remains unclear. These unconventional T cells are polyfunctional innate-like lymphocytes that play a key role in tumor immune surveillance and have a plethora of protective and pathogenic immune responses. The robust anti-tumor potential of γδ T, MAIT, and NKT cells has been established in a variety of preclinical cancer models and in clinical reports. In contrast, recent studies have documented a pro-tumor effect of innate-like T cell subsets that secrete pro-inflammatory cytokines. Consequently, understanding the mechanisms that regulate such T cells and their response to CPI is critical in designing effective cancer immunotherapies that favor anti-tumor immunity. In this Review, we will discuss the current understanding regarding the role of immune checkpoint regulation in γδ T, MAIT, and NKT cells and its importance in anti-cancer immunity.